In working closely with patients and the scientific and regulatory communities, PhaseBio hopes to help those who need novel and innovative therapeutic options.
We currently have a number of clinical trials underway in several cardiovascular indications, including:
A unique ticagrelor reversal agent to treat or prevent major bleeding
We are currently conducting a Phase 2B trial in older (ages 50-64) and elderly (ages 65-80) subjects on dual antiplatelet therapy of ticagrelor and low-dose aspirin, as well as a Phase 3 trial evaluating bentracimab in ticagrelor-treated patients with major bleeding or to enable urgent surgery.
A long-acting VIP analogue to control pulmonary hypertension and improve cardiac function
We are currently conducting a Phase 2B trial in pulmonary arterial hypertension (PAH), as well as a long-term, open label extension study of PB1046 in PAH subjects following completion of the VIP study.
Raymond Benza, MD, professor of medicine at Temple University, College of Medicine and James Magovern chair of cardiovascular research at the Allegheny Health Network, shares the limitations of the current medicines we have to treat the PAH. He provides more information on PhaseBio’s clinical trial investigating PB1046 for the treatment of patients with PAH.
We use essential cookies to make our site work. These enable core functionality such as security and accessibility. Essential cookies are on by default. You can disable these by changing your browser settings, but this may affect how the website functions.
Google Analytics Cookies
We would like to set Google Analytics cookies to help us to improve our website by collecting and reporting information on how you use it. These cookies collect information in a way that does not directly identify anyone.